Long-term effects of caffeine therapy for apnea of prematurity.

BACKGROUND Methylxanthine therapy is commonly used for apnea of prematurity but in the absence of adequate data on its efficacy and safety. It is uncertain whether methylxanthines have long-term effects on neurodevelopment and growth. METHODS We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed. The primary outcome was a composite of death, cerebral palsy, cognitive delay (defined as a Mental Development Index score of <85 on the Bayley Scales of Infant Development), deafness, or blindness at a corrected age of 18 to 21 months. RESULTS Of the 937 infants assigned to caffeine for whom adequate data on the primary outcome were available, 377 (40.2%) died or survived with a neurodevelopmental disability, as compared with 431 of the 932 infants (46.2%) assigned to placebo for whom adequate data on the primary outcome were available (odds ratio adjusted for center, 0.77; 95% confidence interval [CI], 0.64 to 0.93; P=0.008). Treatment with caffeine as compared with placebo reduced the incidence of cerebral palsy (4.4% vs. 7.3%; adjusted odds ratio, 0.58; 95% CI, 0.39 to 0.87; P=0.009) and of cognitive delay (33.8% vs. 38.3%; adjusted odds ratio, 0.81; 95% CI, 0.66 to 0.99; P=0.04). The rates of death, deafness, and blindness and the mean percentiles for height, weight, and head circumference at follow-up did not differ significantly between the two groups. CONCLUSIONS Caffeine therapy for apnea of prematurity improves the rate of survival without neurodevelopmental disability at 18 to 21 months in infants with very low birth weight. (ClinicalTrials.gov number, NCT00182312 [ClinicalTrials.gov].).

[1]  B. Schmidt,et al.  Controversies surrounding xanthine therapy. , 2004, Seminars in neonatology : SN.

[2]  Isaac Ben-Sira,et al.  An international classification of retinopathy of prematurity. Clinical experience. , 1985, Ophthalmology.

[3]  T. Dunwiddie,et al.  The Role and Regulation of Adenosine in the Central Nervous System , 2022 .

[4]  Lucey Jf.  The xanthine treatment of apnea of prematurity. , 1975 .

[5]  A. Pesce,et al.  Standards of laboratory practice: theophylline and caffeine monitoring. National Academy of Clinical Biochemistry. , 1998, Clinical chemistry.

[6]  M. Allen.  Preterm outcomes research: a critical component of neonatal intensive care. , 2002, Mental retardation and developmental disabilities research reviews.

[7]  A. Spitzer,et al.  Reported Medication Use in the Neonatal Intensive Care Unit: Data From a Large National Data Set , 2006, Pediatrics.

[8]  Richard J Martin,et al.  Apnoea of prematurity. , 2004, Paediatric respiratory reviews.

[9]  R. Chaney,et al.  Hemodynamic effects of inotropes during hypothermia and rapid rewarming , 1981, Critical care medicine.

[10]  R W Platt,et al.  A new and improved population-based Canadian reference for birth weight for gestational age. , 2001, Pediatrics.

[11]  D. Brunette,et al.  Successful transcutaneous pacing in 2 severely hypothermic patients. , 2007, Annals of emergency medicine.

[12]  T. Hirose,et al.  An International Classification of Retinopathy of Prematurity: II. The Classification of Retinal Detachment , 1987 .

[13]  B. Schmidt,et al.  Methylxanthine therapy in premature infants: sound practice, disaster, or fruitless byway? , 1999, The Journal of pediatrics.

[14]  A. Patz.  An International Classification of Retinopathy of Prematurity: II. The Classification of Retinal Detachment , 1987 .

[15]  J. Lucey.  The xanthine treatment of apnea of prematurity. , 1975, Pediatrics.

[16]  M. Paech,et al.  Low and Moderate Remifentanil Infusion Rates Do Not Alter Target-Controlled Infusion Propofol Concentrations Necessary to Maintain Anesthesia as Assessed by Bispectral Index Monitoring , 2007, Anesthesia and analgesia.

[17]  J. Gould,et al.  Prospective Evaluation of Postnatal Steroid Administration: A 1-Year Experience From the California Perinatal Quality Care Collaborative , 2006, Pediatrics.

[18]  D. Henderson-smart,et al.  Methylxanthine treatment for apnea in preterm infants. , 2008, The Cochrane database of systematic reviews.

[19]  R. Boutilier,et al.  Mechanisms of cell survival in hypoxia and hypothermia. , 2001, The Journal of experimental biology.

[20]  Mark Schluchter,et al.  Poor Predictive Validity of the Bayley Scales of Infant Development for Cognitive Function of Extremely Low Birth Weight Children at School Age , 2005, Pediatrics.

[21]  N. Finer,et al.  Neonatal apnea: diagnosis by nurse versus computer. , 1988, Pediatrics.

[22]  E. Palmer,et al.  Severity of Neonatal Retinopathy of Prematurity Is Predictive of Neurodevelopmental Functional Outcome at Age 5.5 Years , 2000, Pediatrics.

[23]  R. Palisano,et al.  Development and reliability of a system to classify gross motor function in children with cerebral palsy , 1997, Developmental medicine and child neurology.

[24]  Z. Quezado,et al.  The Anesthetic Management of Children with Neonatal-Onset Multi-System Inflammatory Disease , 2007, Anesthesia and analgesia.

[25]  E. Bancalari.  Caffeine for apnea of prematurity. , 2006, The New England journal of medicine.

[26]  N. Finer,et al.  Summary Proceedings From the Apnea-of-Prematurity Group , 2006, Pediatrics.

[27]  T. Gunn,et al.  Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. , 1977, The Journal of pediatrics.

[28]  N. Bayley.  Manual for the Bayley Scales of Infant Development , 1969 .

[29]  Hee‐Soo Kim,et al.  Changes of bispectral index during recovery from general anesthesia with 2% propofol and remifentanil in children , 2007, Paediatric anaesthesia.

[30]  B B Fredholm,et al.  Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine. , 1995, Pharmacology & toxicology.

[31]  C. Ménigaux,et al.  The Effect of Remifentanil on the Bispectral Index Change and Hemodynamic Responses After Orotracheal Intubation , 2000, Anesthesia and analgesia.

[32]  B. Schmidt,et al.  Impact of Bronchopulmonary Dysplasia, Brain Injury, and Severe Retinopathy on the Outcome of Extremely Low-Birth-Weight Infants at 18 Months: Results From the Trial of Indomethacin Prophylaxis in Preterms , 2003 .

[33]  D L Sackett,et al.  An assessment of clinically useful measures of the consequences of treatment. , 1988, The New England journal of medicine.

[34]  L. Doyle,et al.  Caffeine therapy for apnea of prematurity. , 2006, The New England journal of medicine.

[35]  B. Schmidt.  Methylxanthine Therapy for Apnea of Prematurity: Evaluation of Treatment Benefits and Risks at Age 5 Years in the International Caffeine for Apnea of Prematurity (CAP) Trial , 2005, Neonatology.

[36]  S. Donn,et al.  Minimising ventilator induced lung injury in preterm infants , 2005, Archives of Disease in Childhood - Fetal and Neonatal Edition.

[37]  J. Kuzemko,et al.  Apnoeic attacks in the newborn treated with aminophylline. , 1973, Archives of disease in childhood.